McKesson Co. (NYSE:MCK) has been assigned a consensus rating of “Hold” from the seventeen brokerages that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation and eight have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $144.99.
Several brokerages have recently weighed in on MCK. Royal Bank of Canada reiterated a “hold” rating and set a $152.00 target price on shares of McKesson in a research note on Friday, July 27th. JPMorgan Chase & Co. dropped their price objective on shares of McKesson from $181.00 to $160.00 and set an “overweight” rating for the company in a research note on Friday, July 27th. Barclays lowered their target price on shares of McKesson from $150.00 to $136.00 and set an “equal weight” rating for the company in a research note on Friday, October 26th. Jefferies Financial Group reiterated a “buy” rating and issued a $160.00 price target on shares of McKesson in a report on Friday, July 27th. Finally, ValuEngine lowered shares of McKesson from a “sell” rating to a “strong sell” rating in a report on Friday, November 16th.
MCK opened at $121.16 on Friday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.56 and a current ratio of 0.99. McKesson has a one year low of $117.19 and a one year high of $178.86. The company has a market capitalization of $23.80 billion, a P/E ratio of 9.60, a price-to-earnings-growth ratio of 1.38 and a beta of 1.05.
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, January 2nd. Shareholders of record on Monday, December 3rd will be given a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 1.29%. The ex-dividend date is Friday, November 30th. McKesson’s dividend payout ratio is 12.36%.
In other McKesson news, Director N Anthony Coles sold 1,350 shares of the business’s stock in a transaction that occurred on Friday, August 31st. The shares were sold at an average price of $128.69, for a total value of $173,731.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.87% of the company’s stock.
A number of hedge funds have recently bought and sold shares of MCK. Fort L.P. bought a new stake in McKesson in the second quarter worth approximately $110,000. Flagship Harbor Advisors LLC bought a new stake in shares of McKesson during the 2nd quarter worth $118,000. Reilly Financial Advisors LLC boosted its holdings in shares of McKesson by 506.8% during the 3rd quarter. Reilly Financial Advisors LLC now owns 898 shares of the company’s stock worth $119,000 after buying an additional 750 shares during the period. Bray Capital Advisors bought a new stake in shares of McKesson during the 3rd quarter worth $123,000. Finally, FNY Investment Advisers LLC boosted its holdings in shares of McKesson by 88.6% during the 3rd quarter. FNY Investment Advisers LLC now owns 1,120 shares of the company’s stock worth $148,000 after buying an additional 526 shares during the period. 89.97% of the stock is owned by institutional investors.
McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates in three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as other healthcare-related products; and offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices.
Further Reading: Return on Equity (ROE)
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.